PF-5190457, an inverse agonist for the ghrelin receptor discovered by Pfizer in the mid-2010s as a clinical candidate for diabetes, effectively suppresses GHS-R1a activity, both at its baseline function and in response to ghrelin [91]. This evidence concerns the gene GHSR and diabetes mellitus.